During the open-label phase , continued BMD increases occurred with long-term denosumab treatment ( @ % lumbar spine , @ % total hip , @ % femoral neck , @ % trochanter , and @ % @/@ radius ) , resulting in cumulative @-month gains from baseline of @ % , @ % , @ % , @ % , and @ % , respectively ( all P < @ ) .